We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-6.91%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$488M
AUM Growth
-$65.2M
Cap. Flow
-$17.8M
Cap. Flow %
-3.65%
Top 10 Hldgs %
32.78%
Holding
126
New
4
Increased
19
Reduced
35
Closed
4

Top Buys

Rank Stock Value
1
DHR icon
Danaher
DHR
+$5.8M
2
INCY icon
Incyte
INCY
+$5.8M
3
BCR
CR Bard Inc.
BCR
+$5.67M
4
AKRX
Akorn Inc
AKRX
+$4.79M
5
EW icon
Edwards Lifesciences
EW
+$3.89M

Top Sells

Rank Stock Value
1
CAH icon
Cardinal Health
CAH
+$6.82M
2
ILMN icon
Illumina
ILMN
+$5.64M
3
AMSG
Amsurg Corp
AMSG
+$4.79M
4
SYK icon
Stryker
SYK
+$2.92M
5
CI icon
Cigna
CI
+$2.88M

Sector Composition

Rank Sector Weight
1 Healthcare 91.87%
2 Financials 0.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXN
26
DELISTED
Alexion Pharmaceuticals
ALXN
$6.04M 1.24%
49,400
– –
VRTX icon
27
Vertex Pharmaceuticals
VRTX
$123B
$5.97M 1.22%
81,000
-4,000
-5% -$325K
DHR icon
28
Danaher
DHR
$144B
$5.76M 1.18%
+83,472
New +$5.8M
ISRG icon
29
Intuitive Surgical
ISRG
$122B
$5.71M 1.17%
81,000
-27,000
-25% -$1.99M
BMRN icon
30
BioMarin Pharmaceuticals
BMRN
$11.5B
$5.38M 1.1%
65,000
– –
ABMD
31
DELISTED
Abiomed Inc
ABMD
$5.08M 1.04%
45,050
-10,400
-19% -$1.2M
CI icon
32
Cigna
CI
$74.5B
$5.03M 1.03%
37,722
-22,000
-37% -$2.88M
CHRS icon
33
Coherus Oncology
CHRS
$216M
$4.93M 1.01%
175,000
-27,000
-13% -$756K
CERN
34
DELISTED
Cerner Corp
CERN
$4.67M 0.96%
98,500
– –
ARIA
35
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$4.67M 0.96%
375,000
-120,000
-24% -$1.45M
JNJ icon
36
Johnson & Johnson
JNJ
$609B
$4.38M 0.9%
38,000
-12,000
-24% -$1.39M
IONS icon
37
Ionis Pharmaceuticals
IONS
$8.99B
$4.35M 0.89%
91,000
-17,000
-16% -$673K
SHPG
38
DELISTED
Shire pic
SHPG
$4.09M 0.84%
24,000
-14,090
-37% -$2.5M
MNK
39
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$4.03M 0.82%
80,800
– –
COO icon
40
Cooper Companies
COO
$14B
$3.5M 0.72%
80,000
-14,000
-15% -$611K
ESRX
41
DELISTED
Express Scripts Holding Company
ESRX
$3.4M 0.7%
49,500
– –
MCK icon
42
McKesson
MCK
$98.5B
$3.37M 0.69%
24,000
– –
EGRX
43
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$3.23M 0.66%
40,700
+11,700
+40% +$850K
HUM icon
44
Humana
HUM
$48B
$3.16M 0.65%
15,500
+4,700
+44% +$896K
HALO icon
45
Halozyme
HALO
$9.23B
$3.14M 0.64%
318,000
– –
RARE icon
46
Ultragenyx Pharmaceutical
RARE
$2.88B
$3.02M 0.62%
43,000
– –
ELV icon
47
Elevance Health
ELV
$80.9B
$2.96M 0.61%
20,600
– –
NBIX icon
48
Neurocrine Biosciences
NBIX
$17.2B
$2.9M 0.59%
75,000
+17,000
+29% +$770K
ZLTQ
49
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$2.61M 0.53%
60,000
– –
LLY icon
50
Eli Lilly
LLY
$1.05T
$2.57M 0.53%
35,000
– –
1
2
3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2016 Portfolio in Review

As of Q4 2016, Bellevue Group held 126 positions worth $488M, down 12% from $553M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Bellevue Group withdrew a net $17.8M in Q4 2016, closing 4 positions and reducing 35 holdings. Its most notable exit was Amsurg Corp, an estimated $4.79M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 92% a quarter earlier, followed by Financials.

Against the trend, Bellevue Group opened a new position in Danaher worth $5.76M.

  • Bellevue Group's largest Q4 2016 buy was Danaher: 83,472 shares worth $5.76M.
  • Bellevue Group added most to Incyte in Q4 2016, an estimated $5.8M increase.
  • Bellevue Group's biggest Q4 2016 reduction was Cardinal Health, cutting an estimated $6.82M.
  • Bellevue Group fully exited Amsurg Corp in Q4 2016, selling an estimated $4.79M.
  • Bellevue Group's ten largest holdings make up 33% of its $488M portfolio in Q4 2016.
  • Bellevue Group opened 4 new positions and closed 4 in Q4 2016.
  • Bellevue Group's portfolio value fell 12% quarter-over-quarter to $488M.

Based on Bellevue Group's 13F filing for Q4 2016, filed 10 Feb 2017.